trimethyloxamine has been researched along with Thrombosis in 19 studies
trimethyloxamine: used in manufacture of quaternary ammonium cpds; insect attractant; warming agent for gas; oxidant; structure
trimethylamine N-oxide : A tertiary amine oxide resulting from the oxidation of the amino group of trimethylamine.
Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gut microbes influence cardiovascular disease and thrombosis risks through the production of trimethylamine N-oxide (TMAO)." | 5.27 | Microbial Transplantation With Human Gut Commensals Containing CutC Is Sufficient to Transmit Enhanced Platelet Reactivity and Thrombosis Potential. ( DiDonato, JA; Fischbach, MA; Guo, CJ; Haag, B; Hazen, SL; Jia, X; Kirsop, J; Lang, JM; Lusis, AJ; Rey, FE; Romano, KA; Skye, SM; Tang, WHW; Wang, Z; Zhu, W, 2018) |
| "Endothelial TF contributes to TMAO-related arterial thrombosis potential, and can be specifically blocked by targeted non-lethal inhibition of gut microbial choline TMA-lyase." | 4.12 | Vascular endothelial tissue factor contributes to trimethylamine N-oxide-enhanced arterial thrombosis. ( Buffa, JA; DiDonato, JA; Friebel, J; Haghikia, A; Hazen, SL; Kirchhofer, D; Landmesser, U; Li, L; Li, XS; Lüscher, TF; Mach, F; Matter, CM; Räber, L; Rauch, U; Sangwan, N; Tang, WHW; Tizian, C; Wang, Z; Witkowski, M, 2022) |
| " Furthermore, unlike chronic dietary choline, TML supplementation in mice failed to elevate plasma TMAO or heighten thrombosis potential in vivo." | 3.88 | Untargeted metabolomics identifies trimethyllysine, a TMAO-producing nutrient precursor, as a predictor of incident cardiovascular disease risk. ( Allayee, H; Buffa, JA; Cajka, T; DiDonato, JA; Fiehn, O; Gu, X; Han, Y; Hartiala, JA; Hazen, SL; Hurd, AG; Kerby, RL; Li, L; Li, XS; Lüscher, TF; Nemet, I; Obeid, S; Rey, FE; Roberts, AB; Romano, KA; Shahen, CJ; Skye, SM; Tang, WHW; Wagner, MA; Wang, Z; Wu, Y, 2018) |
| "Phenylacetylglutamine, for example, was recently shown to promote adverse cardiovascular phenotypes in the host via interaction with multiple ARs (adrenergic receptors)-a class of key receptors that regulate cardiovascular homeostasis." | 2.66 | Gut Microbiota and Cardiovascular Disease. ( Hazen, SL; Weeks, TL; Witkowski, M, 2020) |
| "Trimethylamine (TMA) is a tertiary amine with a characteristic fishy odour." | 2.53 | The complex metabolism of trimethylamine in humans: endogenous and exogenous sources. ( Bhargava, B; Chhibber-Goel, J; Gaur, A; Parakh, N; Sharma, A; Singhal, V, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (68.42) | 24.3611 |
| 2020's | 6 (31.58) | 2.80 |
| Authors | Studies |
|---|---|
| Tu, R | 1 |
| Xia, J | 1 |
| Papa, A | 1 |
| Santini, P | 1 |
| De Lucia, SS | 1 |
| Maresca, R | 1 |
| Porfidia, A | 1 |
| Pignatelli, P | 1 |
| Gasbarrini, A | 1 |
| Violi, F | 1 |
| Pola, R | 1 |
| Gong, D | 1 |
| Zhang, L | 1 |
| Zhang, Y | 1 |
| Wang, F | 1 |
| Zhao, Z | 1 |
| Zhou, X | 1 |
| Berger, M | 1 |
| Kleber, ME | 1 |
| Delgado, GE | 1 |
| März, W | 1 |
| Andreas, M | 1 |
| Hellstern, P | 1 |
| Marx, N | 1 |
| Schuett, KA | 1 |
| Gencer, B | 1 |
| Li, XS | 3 |
| Gurmu, Y | 1 |
| Bonaca, MP | 1 |
| Morrow, DA | 1 |
| Cohen, M | 1 |
| Bhatt, DL | 1 |
| Steg, PG | 1 |
| Storey, RF | 1 |
| Johanson, P | 1 |
| Wang, Z | 7 |
| Hazen, SL | 8 |
| Sabatine, MS | 1 |
| Witkowski, M | 3 |
| Weeks, TL | 1 |
| Friebel, J | 1 |
| Buffa, JA | 3 |
| Sangwan, N | 1 |
| Li, L | 3 |
| DiDonato, JA | 4 |
| Tizian, C | 1 |
| Haghikia, A | 1 |
| Kirchhofer, D | 1 |
| Mach, F | 1 |
| Räber, L | 1 |
| Matter, CM | 1 |
| Tang, WHW | 5 |
| Landmesser, U | 1 |
| Lüscher, TF | 2 |
| Rauch, U | 1 |
| Zhu, W | 4 |
| Subramaniam, S | 1 |
| Fletcher, C | 1 |
| Ascher, S | 1 |
| Reinhardt, C | 1 |
| Cajka, T | 1 |
| Nemet, I | 1 |
| Hurd, AG | 1 |
| Gu, X | 1 |
| Skye, SM | 2 |
| Roberts, AB | 1 |
| Wu, Y | 2 |
| Shahen, CJ | 1 |
| Wagner, MA | 1 |
| Hartiala, JA | 1 |
| Kerby, RL | 1 |
| Romano, KA | 2 |
| Han, Y | 1 |
| Obeid, S | 1 |
| Allayee, H | 2 |
| Rey, FE | 2 |
| Fiehn, O | 1 |
| Guo, CJ | 1 |
| Jia, X | 2 |
| Kirsop, J | 1 |
| Haag, B | 1 |
| Lang, JM | 1 |
| Lusis, AJ | 3 |
| Fischbach, MA | 1 |
| van Mens, TE | 1 |
| Büller, HR | 1 |
| Nieuwdorp, M | 1 |
| Cheng, X | 1 |
| Qiu, X | 1 |
| Liu, Y | 1 |
| Yuan, C | 1 |
| Yang, X | 1 |
| Shih, DM | 1 |
| Schugar, RC | 1 |
| Meng, Y | 1 |
| Miikeda, A | 1 |
| Zieger, M | 1 |
| Lee, R | 1 |
| Graham, M | 1 |
| Cantor, RM | 1 |
| Mueller, C | 1 |
| Brown, JM | 2 |
| Gregory, JC | 1 |
| Org, E | 1 |
| Gupta, N | 1 |
| Fu, X | 1 |
| Mehrabian, M | 1 |
| Sartor, RB | 1 |
| McIntyre, TM | 1 |
| Silverstein, RL | 1 |
| Chhibber-Goel, J | 1 |
| Gaur, A | 1 |
| Singhal, V | 1 |
| Parakh, N | 1 |
| Bhargava, B | 1 |
| Sharma, A | 1 |
| Tilg, H | 1 |
| Lippi, G | 1 |
| Danese, E | 1 |
| Mattiuzzi, C | 1 |
| Favaloro, EJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562] | Phase 3 | 21,379 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Effects of a Whole Food Based Nutritional Formulation on Trimethylamine N-oxide and Cardiometabolic Endpoints in Healthy Adults.[NCT05795946] | 45 participants (Anticipated) | Interventional | 2023-04-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 5.1 |
| Ticagrelor 60 mg | 4.7 |
| Placebo | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.6 |
| Ticagrelor 60 mg | 2.3 |
| Placebo | 1.1 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.9 |
| Ticagrelor 60 mg | 2.9 |
| Placebo | 3.4 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 7.8 |
| Ticagrelor 60 mg | 7.8 |
| Placebo | 9.0 |
7 reviews available for trimethyloxamine and Thrombosis
| Article | Year |
|---|---|
Stroke and Vascular Cognitive Impairment: The Role of Intestinal Microbiota Metabolite TMAO.
Topics: Choline; Cognitive Dysfunction; Gastrointestinal Microbiome; Humans; Inflammation; Stroke; Thrombosi | 2024 |
Gut dysbiosis-related thrombosis in inflammatory bowel disease: Potential disease mechanisms and emerging therapeutic strategies.
Topics: Dysbiosis; Endotoxemia; Gastrointestinal Diseases; Humans; Inflammatory Bowel Diseases; Lipopolysacc | 2023 |
Gut Microbiota and Cardiovascular Disease.
Topics: Animals; Atherosclerosis; Bile Acids and Salts; Cardiovascular Diseases; Carnitine; Choline; Disease | 2020 |
Trimethylamine N-oxide: breathe new life.
Topics: Animals; Brain Diseases; Heart Failure; Humans; Methylamines; Neoplasms; Obesity; Thrombosis | 2018 |
The gut microbiota: An emerging risk factor for cardiovascular and cerebrovascular disease.
Topics: Animals; Atherosclerosis; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Gastr | 2018 |
The complex metabolism of trimethylamine in humans: endogenous and exogenous sources.
Topics: Air Pollutants; Animals; Atherosclerosis; Diet; Humans; Metabolism, Inborn Errors; Methylamines; Neo | 2016 |
The Intriguing Link between the Intestinal Microbiota and Cardiovascular Disease.
Topics: Bacteria; Gastrointestinal Microbiome; Gastrointestinal Tract; Humans; Methylamines; Myocardial Isch | 2017 |
2 trials available for trimethyloxamine and Thrombosis
| Article | Year |
|---|---|
Gut Microbe-Generated Trimethylamine
Topics: Adult; Aspirin; Choline; Dietary Fats; Female; Gastrointestinal Microbiome; Humans; Male; Methylamin | 2017 |
Microbial Transplantation With Human Gut Commensals Containing CutC Is Sufficient to Transmit Enhanced Platelet Reactivity and Thrombosis Potential.
Topics: Adult; Animals; Bacterial Proteins; Choline; Clostridium; Fecal Microbiota Transplantation; Female; | 2018 |
10 other studies available for trimethyloxamine and Thrombosis
| Article | Year |
|---|---|
Gut Microbial Metabolite Trimethylamine N-Oxide Is Related to Thrombus Formation in Atrial Fibrillation Patients.
Topics: Atrial Fibrillation; Female; Gastrointestinal Microbiome; Humans; Male; Methylamines; Middle Aged; P | 2019 |
Trimethylamine N-Oxide and Adenosine Diphosphate-Induced Platelet Reactivity Are Independent Risk Factors for Cardiovascular and All-Cause Mortality.
Topics: Biomarkers; Cardiovascular Diseases; Humans; Methylamines; Mortality; Platelet Activation; Thrombosi | 2020 |
Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial.
Topics: Aged; Aspirin; Bacteria; Case-Control Studies; Dual Anti-Platelet Therapy; Female; Gastrointestinal | 2020 |
Vascular endothelial tissue factor contributes to trimethylamine N-oxide-enhanced arterial thrombosis.
Topics: Animals; Choline; Endothelial Cells; Humans; Lyases; Methylamines; Mice; Thromboplastin; Thrombosis | 2022 |
Untargeted metabolomics identifies trimethyllysine, a TMAO-producing nutrient precursor, as a predictor of incident cardiovascular disease risk.
Topics: Aged; Animals; Atherosclerosis; Cardiovascular Diseases; Carnitine; Cholesterol; Choline; Disease Mo | 2018 |
Targeted inhibition of gut microbiota proteins involved in TMAO production to reduce platelet aggregation and arterial thrombosis: a blueprint for drugging the microbiota in the treatment of cardiometabolic disease?
Topics: Gastrointestinal Microbiome; Humans; Methylamines; Microbiota; Platelet Aggregation; Thrombosis | 2019 |
Trimethylamine N-oxide promotes tissue factor expression and activity in vascular endothelial cells: A new link between trimethylamine N-oxide and atherosclerotic thrombosis.
Topics: Aged; Atherosclerosis; Cells, Cultured; Endothelial Cells; Female; Humans; Male; Methylamines; Middl | 2019 |
Genetic Deficiency of Flavin-Containing Monooxygenase 3 ( Fmo3) Protects Against Thrombosis but Has Only a Minor Effect on Plasma Lipid Levels-Brief Report.
Topics: Animals; Atherosclerosis; Choline; Disease Models, Animal; Lipid Metabolism; Methylamines; Mice; Mic | 2019 |
Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk.
Topics: Animals; Blood Platelets; Calcium; Carotid Artery Injuries; Cecum; Chlorides; Choline; Diet; Female; | 2016 |
A Gut Feeling about Thrombosis.
Topics: Animals; Choline; Gastrointestinal Microbiome; Humans; Methylamines; Mice; Plasmalogens; Risk Factor | 2016 |